Subscribe to RSS
DOI: 10.1055/s-0030-1262655
© Georg Thieme Verlag KG Stuttgart ˙ New York
Diabetische Nephropathie und Hypertonie
Publication History
Publication Date:
20 December 2010 (online)

Einleitung
Neben dem Diabetes mellitus kommt der arteriellen Hypertonie eine wesentliche Bedeutung für die Entwicklung arteriosklerotischer Erkrankungen zu. Bei Hypertoniepatienten spielt die Kontrolle des Blutdruckes eine entscheidende Rolle zur Verbesserung des kardiovaskulären Outcomes und der Vermeidung mikrovaskulärer Komplikationen. Dies gilt umso mehr in Hochrisikokollektiven wie bei Patienten mit Diabetes mellitus. Bedingt durch die drastische Zunahme von Typ-2-Diabetikern in den letzten Jahrzehnten ist auch eine Zunahme der diabetischen Nephropathie zu verzeichnen – heutzutage stellt diese Krankheitsentität die häufigste Ursache für eine dialysepflichtige terminale Niereninsuffizienz in den westlichen Industrieländern dar. Zusätzlich bedeutet bereits eine geringe Einschränkung der glomerulären Filtrationsrate einen weiteren kardiovaskulären Risikofaktor. Beiden Erkrankungen gemein ist die Albuminurie als Screeningmarker für einen renalen Endorganschaden.
In diesem CME-Modul soll als Schwerpunkt die Interaktion zwischen diabetischer Nephropathie und Hypertonie bearbeitet werden. Warum erkranken viele Diabetiker an einer arteriellen Hypertonie? Wie kann die Progression der diabetischen Nephropathie durch Behandlung der arteriellen Hypertonie beeinflusst werden? Welche therapeutischen Optionen sind in den unterschiedlichen Stadien sinnvoll? Insbesondere die Frage nach den Zielblutdruckwerten ist durch neue klinische Studienergebnisse im Fluss und bedarf einer Einordnung.
Literatur
- 1
Hasslacher C, Ritz E, Wahl P et al.
Similar risks of nephropathy in patients with type I or type II diabetes mellitus.
Nephrol Dial Transplant.
1989;
4
859-863
MissingFormLabel
- 2
Verhave J C, Hillege H L, Burgerhof J G PREVEND Study Group et al.,.
Cardiovascular risk factors are differently associated with urinary albumin excretion
in men and women.
J Am Soc Nephrol.
2003;
14
1330-1335
MissingFormLabel
- 3
Hasslacher C, Wolf G, Kempe P et al.
Diabetische Nephropathie.
Diabetologie.
2008;
3 (Suppl. 2)
S143-S146
MissingFormLabel
- 4
Parving H H, Hommel E, Mathiesen E et al.
Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy
in patients with insulin dependent diabetes.
Br Med J (Clin Res Ed).
1988;
296
156-160
MissingFormLabel
- 5
Lurbe E, Redon J, Kesani A et al.
Increase in nocturnal blood pressure and progression to microalbuminuria in type 1
diabetes.
N Engl J Med.
2002;
347
797-805
MissingFormLabel
- 6
Redon J, Cifkova R, Laurent S et al.
Mechanisms of hypertension in the cardiometabolic syndrome.
J Hypertens.
2009;
27
441-451
MissingFormLabel
- 7
Lang F, Klingel K, Wagner C A et al.
Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic
nephropathy.
Proc Natl Acad Sci U S A.
2000;
97
8157-8162
MissingFormLabel
- 8
Perrotti N, He R A, Phillips S A et al.
Activation of serum- and glucocorticoid-induced protein kinase (Sgk) by cyclic AMP
and insulin.
J Biol Chem.
2001;
276
9406-9412
MissingFormLabel
- 9
Tiwari S, Riazi S, Ecelbarger C A.
Insulin's impact on renal sodium transport and blood pressure in health, obesity,
and diabetes.
Am J Physiol Renal Physiol.
2007;
293
F974-F984
MissingFormLabel
- 10
Boini K M, Hennige A M, Huang D Y et al.
Serum- and glucocorticoid-inducible kinase 1 mediates salt sensitivity of glucose
tolerance.
Diabetes.
2006;
55
2059-2066
MissingFormLabel
- 11
Ohashi K, Kihara S, Ouchi N et al.
Adiponectin replenishment ameliorates obesity-related hypertension.
Hypertension.
2006;
47
1108-1116
Erratum in: Hypertension 2007; 49: e14
MissingFormLabel
- 12
Bakris G L, Williams M, Dworkin L et al.
Preserving renal function in adults with hypertension and diabetes: A consensus approach.
National Kidney Foundation Hypertension and Diabetes Executive Committees Working
Group.
Am J Kidney Dis.
2000;
36
646-661
MissingFormLabel
- 13
ACCORD Study Group .
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
N Engl J Med.
2010;
362
1575-1585
MissingFormLabel
- 14
Eijkelkamp W B, Zhang Z, Remuzzi G et al.
Albuminuria is a target for renoprotective therapy independent from blood pressure
in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction
of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
J Am Soc Nephrol.
2007;
18
1540-1546
MissingFormLabel
- 15
de Galan B E, Perkovic V, Ninomiya T ADVANCE Collaborative Group et al.,.
Lowering blood pressure reduces renal events in type 2 diabetes.
J Am Soc Nephrol.
2009;
20
883-892
MissingFormLabel
- 16
Appel L J, Wright Jr J T, Greene T AASK Collaborative Research Group et al.,.
Intensive blood-pressure control in hypertensive chronic kidney disease.
N Engl J Med.
2010;
363
918-929
MissingFormLabel
- 17
Holman R R, Paul S K, Bethel M A et al.
10-year follow-up of intensive glucose control in type 2 diabetes.
N Engl J Med.
2008;
359
1577-1589
MissingFormLabel
- 18
Ott P, Benke I, Stelzer J et al.
„Diabetes in Germany” (DIG) Study. A prospective 4-year-follow-up study on the quality
of treatment for type 2 diabetes in daily practice.
Dtsch Med Wochenschr.
2009;
134
291-297
MissingFormLabel
- 19
Abuissa H, Jones P G, Marso S P et al.
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention
of type 2 diabetes: a meta-analysis of randomized clinical trials.
J Am Coll Cardiol.
2005;
46
821-826
MissingFormLabel
- 20
Elliott W J, Meyer P M.
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.
Lancet.
2007;
369
201-207
MissingFormLabel
- 21
Lewis E J, Hunsicker L G, Bain R P et al.
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The
Collaborative Study Group.
N Engl J Med.
1993;
329
1456-1462
MissingFormLabel
- 22
Ruggenenti P, Fassi A, Ilieva A P Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators et al.,.
Preventing microalbuminuria in type 2 diabetes.
N Engl J Med.
2004;
351
1941-1951
MissingFormLabel
- 23
Mauer M, Zinman B, Gardiner R et al.
Renal and retinal effects of enalapril and losartan in type 1 diabetes.
N Engl J Med.
2009;
361
40-51
MissingFormLabel
- 24
Perkins B A, Ficociello L H, Silva K H et al.
Regression of microalbuminuria in type 1 diabetes.
N Engl J Med.
2003;
348
2285-2293
MissingFormLabel
- 25
Casas J P, Chua W, Loukogeorgakis S et al.
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs
on renal outcomes: systematic review and meta-analysis.
Lancet.
2005;
366
2026-2033
Review
MissingFormLabel
- 26
Barnett A H, Bain S C, Bouter P Diabetics Exposed to Telmisartan and Enalapril Study Group et al.
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes
and nephropathy.
N Engl J Med.
2004;
351
1952-1961
MissingFormLabel
- 27
Bakris G, Burgess E, Weir M AMADEO Study Investigators et al.,.
Telmisartan is more effective than losartan in reducing proteinuria in patients with
diabetic nephropathy.
Kidney Int.
2008;
74
364-369
MissingFormLabel
- 28
Brenner B M, Cooper M E, de Zeeuw D RENAAL Study Investigators et al.,.
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes
and nephropathy.
N Engl J Med.
2001;
345
861-869
MissingFormLabel
- 29
Mann J F, Schmieder R E, Dyal L TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with
Cardiovascular Disease) Investigators et al.,.
Effect of telmisartan on renal outcomes: a randomized trial.
Ann Intern Med.
2009;
151
1-10
W 1–2
MissingFormLabel
- 30
Mann J F, Schmieder R E, McQueen M ONTARGET investigators et al.,.
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk
(the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Lancet.
2008;
372
547-553
MissingFormLabel
- 31
Ingelfinger J R.
Aliskiren and dual therapy in type 2 diabetes mellitus.
N Engl J Med.
2008;
358
2503-2505
MissingFormLabel
- 32
Parving H H, Persson F, Lewis J B AVOID Study Investigators et al.,.
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
N Engl J Med.
2008;
358
2433-2446
MissingFormLabel
- 33
Jamerson K, Weber M A, Bakris G L ACCOMPLISH Trial Investigators et al.,.
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
N Engl J Med.
2008;
359
2417-2428
MissingFormLabel
- 34
Sever P S, Dahlöf B, Poulter N R ASCOT investigators et al.,.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients
who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian
Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised
controlled trial.
Lancet.
2003;
361
1149-1158
MissingFormLabel
- 35
Bakris G L, Sarafidis P A, Weir M R ACCOMPLISH Trial investigators et al.
Renal outcomes with different fixed-dose combination therapies in patients with hypertension
at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis
of a randomised controlled trial.
Lancet.
2010;
375
1173-1181
MissingFormLabel
Priv.-Doz. Dr. med. B. Friedrich
Nephrologische Gemeinschaftspraxis Leonberg
Steinbeisstraße 4–6
71229 Leonberg
Email: bjoern.friedrich1@gmx.de